Gritstone bio announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until December 2019.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
- Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
- Gritstone publishes interim results from Phase 1/2 study of SLATE
- Gritstone presents improvements to EDGE Platform at AACR 2024
- Biotech Alert: Searches spiking for these stocks today